

## Program

9<sup>th</sup> Cancer Crosslinks 2017

January 26, 2017 – Ullernchausseen 64-66, entrance 2b, Oslo Cancer Cluster Innovation Park

08:30h - 09:15h <b>REGISTRATION &amp; COFFEE</b>	
<b>Session 1: Cancer and Inflammation – new insights and their clinical impact</b>	
Chairperson: Anna K. Winge-Main, Senior Oncologist, Dept. of Oncology, Oslo University Hospital	
09:15h - 09:20h	Welcome note - Oslo Cancer Cluster
09:20h - 09:30h	Introduction by Anna K. Winge-Main, Oslo University Hospital
09:30h - 10:20h	<b>Opening Keynote:</b> Cancer and Inflammation <i>Prof. Jérôme Galon, Ph.D., Research Director at INSERM; Head of the INSERM Integrative Cancer Immunology Laboratory, Cordeliers Research Center, Paris, France</i>
10:20h - 10:50h	<b>International Keynote:</b> Inflammation lights the way to metastasis. <i>Dr. Seth B. Coffelt, Head of Immune Cells and Metastasis Group, Cancer Research UK Beatson Institute, Institute of Cancer Sciences, University of Glasgow, UK</i>
10:50h - 11:20h	<b>COFFEE &amp; NETWORKING BREAK</b>
11:20h - 11:50h	<b>International Keynote:</b> The gut microbiota, inflammation and cancer <i>Prof. Julian Marchesi, Professor of Digestive Health, Faculty of Medicine, Department of Surgery &amp; Cancer, Imperial College London, UK</i>
11:50h - 12:10h	Inflammation Research in Norway – core expertise and collaboration opportunities <i>Prof. Guttorm Haraldsen, Head of KG Jebsen Inflammation Research Center, Oslo</i>
<b>Session 2: Today's cancer treatment: how individualized can it be?</b>	
Chairpersons: Alexander Fosså and Åse Bratland, Senior Oncologists Oslo University Hospital	
12:10h - 12:20h	Introduction by Chairpersons
12:20h - 13:15h	<b>International Keynote:</b> Hematological cancers: how individualized can we treat patients today? <i>Prof. William G. Wierda, M.D., Ph.D.; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA</i>
13:15h - 14:15h	<b>LUNCH &amp; NETWORKING BREAK</b>
14:15h - 14:40h	<b>Case Study:</b> Personalized Screening Platform and implications for clinical practice <i>Dr. Yngvar Fløisand, Senior Consultant &amp; Dr. Jorrit Enserink, Group Leader; Oslo University Hospital</i>
14:40h - 15:10h	<b>International Keynote:</b> The role of clinical -omics for precision medicine approaches in hematology <i>Dr. Anna Schuh, Director of Molecular Diagnostics in the Department of Oncology; Honorary Consultant Hematologist at Oxford University Hospitals Trust, UK</i>
<b>Session 3: Classical endpoints vs. real-world evidence: need to rethink?</b>	
15:10h - 15:30h	<b>Introduction to the topic:</b> From data generation to clinical use: real world evidence as new way to go? <i>Per Harald Fuglerud, Senior Advisor, The Norwegian Medicines Agency</i>
15:30h - 16:15h	<b>Panel Discussion</b> moderated by Benedikte Thunes-Akre, BMS and Hilde Enserink, AbbVie <b>PANELISTS:</b> <i>Prof. Steinar Aamdal, Oslo University Hospital</i> <i>Dr. Espen Enerly, The Norwegian Cancer Registry</i> <i>Ivar Sønbo Kristiansen, Prof. Emeritus, Department of Health Management and Health Economics, University of Oslo</i> <i>Per Harald Fuglerud, Senior Advisor, Statistician; The Norwegian Medicines Agency</i>
From 16:15h	<b>NETWORKING WITH TAPAS &amp; REFRESHMENTS</b>